Safety, Pharmacokinetics and Antiviral Effect of BI 201335 NA in HCV-1 Infected Patients Treated for 28 Days for Treatment naive and Experienced Patients Treated in Combination With Peg Interferon Alfa-2a and Ribavirin
Phase of Trial: Phase II
Latest Information Update: 09 Jul 2015
At a glance
- Drugs Faldaprevir (Primary) ; Peginterferon alfa; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 26 Apr 2012 Official title amended as reported by ClinicalTrials.gov.
- 26 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.